| 2,828 | 104 | 81 |
| 下载次数 | 被引频次 | 阅读次数 |
《分拆规定》的正式出台,使分拆上市可供选择的路径增多,公众对分拆上市的关注度也迅速提升。辽宁成大曾多次尝试将成大生物分拆上市,以前均未在场内市场成功,此次新政策实施后积极参与并取得一定进展。基于动态视角,对案例公司辽宁成大分拆历程进行剖析,分析其选择分拆上市的动因,梳理可能的上市路径,以此为筹划分拆上市的公司提供经验参考。研究结果表明:上市公司分拆所属子公司上市的路径受相关政策影响巨大,行业竞争是分拆上市的催化剂,持续良好的经营业绩是分拆上市的主要保障;不同的分拆路径各有适合的公司类型,分拆上市路径的选择应与公司的发展战略相适应。
Abstract：The policy of spin-off and domestic listing of the listed companies has been officially issued, which has increased the alternative paths and raised the public′s attention rapidly. Liaoning Chengda has tried to spin off and list Chengda biology for many times, but it has not succeeded in the on-site market yet. After the implementation of the new policy, it actively participated in and applied for registering and listing on the Science and Innovation Board of Shanghai Stock Exchange. However, the listing process became slow in the later stage. Based on the dynamic perspective, this study analyzes the process of the spin-off, the reasons and effects of Liaoning Chengda′s previous attempts; Secondly, it combs the listing selection path and analyzes and compares different listing locations, listing plates and strategy combinations; Finally, the suitability of the latest spin-off path selection of the case company, the reasons for the slow progress in the later stage and the possible failure risk are reviewed. This study draws some conclusions and enlightenment to provide some experience reference for the companies to be listed. The results show that the listing path of spin-off subsidiaries is greatly affected by relevant policies, while industry competition is the catalyst for spin-off, and continuous good operating performance is the main guarantee for spin-off; different types are suitable for different spin-off paths, which need to combine with the company′s strategy.
[1] 蒋叶琴.境内上市公司分拆上市的路径分析[J].经济视角(上),2012(5):62-63,61.
[2] 上市公司分拆所属子公司境内上市试点若干规定[EB/OL].(2019-12-13)[2021-03-18].http://www.csrc.gov.cn/pub/zjhpublic/zjh/201912/t20191213_367507.htm.
[3] 王化成，程小可.分拆上市与母公司股权价值研究：“同仁堂”分拆子公司上市的实证分析[J].管理世界，2003(4):112-121.
[4] 林凌.上市公司面对二板市场的选择：分拆上市[J].证券市场导报，2000(7):36-42.
[5] 肖爱晶，耿辉建.企业分拆上市的动因及绩效研究[J].财会通讯，2019(4):52-56.
[6] 王知一.医药企业选择分拆上市动因分析 [J].合作经济与科技，2021(3):66-67.
[7] 朱馨玉.企业整体上市的动因和财务效应研究：以哈药集团整体上市为例[J].市场论坛，2019(3):31-34.
[8] MASHWANI A I,DEREEPER S,DOWLING M,et al.Learning the wealth effects from equity carve-outs[J].Finance research letters,2020,33:1-10.
[9] OWERS J E,SERGI B S.The ongoing contributions of spin-off research and practice to understanding corporate restructuring and wealth creation:■100 billion in 1 decade[J].Humanities and social sciences communications,2021,8:1-8.
[10] 何璐伶.中国铁建分拆上市路径选择及市场反应研究[J].商业会计，2019(6):23-28.
[11] 习近平.共建创新包容的开放型世界经济：在首届中国国际进口博览会开幕式上的主旨演讲[J].中华人民共和国国务院公报，2018(33):5-8.
[12] 关于在上海证券交易所设立科创板并试点注册制的实施意见[EB/OL].(2019-01-30)[2021-03-18].http://www.csrc.gov.cn/pub/zjhpublic/zjh/201901/t20190130_350485.htm.
[13] 吴晓璐.“A拆A”热情高涨：71家公司公布分拆计划或意向已有4家子公司上市[N].证券日报，2021-07-02(B01).
[14] 中国证监会关于全国中小企业股份转让系统挂牌公司转板上市的指导意见[EB/OL].(2020-06-03)[2021-03-18].http://www.gov.cn/zhengce/zhengceku/2020-06/04/5517147/files/acd3a38531c44d9fa35481d39962f1ac.pdf.
[15] 辽宁成大股份有限公司2018年年度报告[EB/OL].(2019-04-29)[2021-05-10].http://static.sse.com.cn/disclosure/listedinfo/announcement/c/2019-04-29/600739_2018_n.pdf.
[16] 辽宁成大股份有限公司2020年年度报告[EB/OL].(2021-04-29)[2021-05-10].http://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2021-04-29/600739_20210429_6.pdf.
[17] 辽宁成大生物股份有限公司年度报告(2020)[EB/OL].(2021-03-30) [2021-05-10].http://www.cdbio.cn/upload/file/20210330/20210330095814_4061.pdf.
[18] 辽宁成大生物股份有限公司首次公开发行股票并在科创板上市招股说明书(注册稿)[EB/OL].(2020-11-25)[2021-05-10].http://static.sse.com.cn/stock/information/c/202011/5092f764774045389e78214b1ab5885e.pdf.
[19] 辽宁成大生物股份有限公司关于公司终止发行H股股票并在香港联合交易所上市的公告[EB/OL].(2019-07-30)[2021-05-10].http://www.neeq.com.cn/disclosure/2019/2019-07-30/1564473547_767597.pdf.
[20] 前次募集资金使用情况鉴证报告[EB/OL].(2018-05-04)[2021-05-10].http://www.neeq.com.cn/disclosure/2018/2018-05-04/1525425508_356461.pdf.
[21] 辽宁成大生物股份有限公司首次公开发行股票并在科创板上市申请文件的审核问询函之回复[EB/OL].(2020-09-30)[2021-05-10].http://static.sse.com.cn/stock/information/c/202009/5ffaaf75d6a042389cb63c1c618563e2.pdf.
基本信息:
DOI：10.16433/j.cnki.cn41-1379.2021.05.004
中图分类号:F279.26
引用信息:
[1]赵慧芬,卢继科.上市公司分拆所属子公司上市的路径思考——基于辽宁成大分拆成大生物的案例分析[J].河南工业大学学报(社会科学版),2021,37(05):26-34+120.DOI:10.16433/j.cnki.cn41-1379.2021.05.004.